Metropolis Healthcare Limited announced the launch of its Centre of Genomics on Tuesday, January 13, representing a major strategic expansion into precision diagnostics, molecular testing and genomic research in India. The initiative positions the diagnostics chain to significantly enhance its capabilities in advanced genetic testing and analysis.

Infrastructure and Laboratory Network

The Centre of Genomics will be supported by two CAP-accredited genomics laboratories strategically located in Mumbai and Delhi NCR. These facilities will focus on delivering high-impact clinical services across multiple specialties:

Technology Platform and Expansion Plans

Metropolis Healthcare has outlined ambitious growth targets for its genomic testing capabilities. The company plans to expand its genomic portfolio from the current base of more than 220 validated assays to over 500 advanced tests within the next two to three years.

As part of the technological infrastructure, Metropolis has deployed Illumina's NovaSeq X Series sequencing platform specifically for research purposes. This platform significantly enhances throughput and accuracy in genomic analysis while strengthening the company's next-generation sequencing (NGS) infrastructure and supporting advanced bioinformatics and clinical interpretation.

Leadership Vision and Clinical Integration

Ameera Shah, Promoter and Executive Chairperson of Metropolis Healthcare Limited, explained that the Centre of Genomics brings together orthogonal, cross-platform technologies with advanced data analytics and AI-driven trend correlations. The approach is supported by strong clinical stewardship from subject-matter experts, a multi-specialty Medical Advisory Board, and dedicated clinical support teams, enabling the company to build one of India's most comprehensive and clinically integrated genomic diagnostic platforms.

Dr. Kirti Chadha, Chief Scientific and Innovation Officer at Metropolis Healthcare, emphasized that the Centre aims to translate advanced genomic science into actionable clinical insights. The Centre of Genomics is benchmarked against leading global genomic laboratories in terms of breadth, quality, and clinical integration, while remaining closely aligned to India-specific disease patterns and care pathways.

Strategic Applications and Partnerships

The centre will serve multiple strategic functions beyond routine diagnostic testing. It will operate as a platform for AI-enabled analytics, continuous test development and deeper digital integration. Additionally, the facility will support pharmaceutical programs, clinical trials and global research partnerships, expanding Metropolis Healthcare's role in the broader healthcare ecosystem.

Suchita Dayanand, Country Head – India (Commercial) at Illumina, noted that as Illumina expands its presence in India, the mission is to make advanced sequencing technologies more accessible across the country.

Recent Financial Performance

In its Q3 business update released earlier this month, Metropolis Healthcare reported strong financial performance with consolidated revenue increasing 26.00% year-on-year. This growth was driven by sustained momentum in preventive and wellness checkups under TruHealth, along with a strong increase in specialty testing volumes across both B2C and B2B channels.

The standalone revenue growth of approximately 15.00% was attributed to increased patient and test volumes and a favourable shift in product mix and realisations. Shares of Metropolis Healthcare opened in green on Tuesday and were trading flat at ₹1,876.30 as of 11.49 am.

Metropolis Healthcare has launched two accredited genomics laboratories in Delhi NCR and Mumbai, representing a strategic expansion of its diagnostic capabilities in the genomics sector. The new facilities are designed to cater to specialized medical areas requiring advanced genetic testing and analysis.

Laboratory Focus Areas

The newly established genomics labs will concentrate on five key clinical specialties that require sophisticated genetic testing capabilities:

Strategic Expansion Plans

Metropolis Healthcare has outlined ambitious growth targets for its genomics testing portfolio. The company aims to expand its genomic test offerings to over 500 tests across major clinical areas. This expansion represents a significant commitment to advancing genetic diagnostics capabilities in the Indian healthcare market.

Geographic Coverage

The two accredited laboratories are strategically positioned in India's major metropolitan areas:

• Delhi NCR: Serving the National Capital Region and northern India
• Mumbai: Covering western India and the financial capital's healthcare needs

These locations provide access to large patient populations and established healthcare infrastructure, enabling efficient service delivery across multiple clinical specialties.

Clinical Impact

The establishment of these specialized genomics laboratories enhances the company's ability to provide comprehensive genetic testing services. The focus on oncology, reproductive health, neurology, transplant immunology, and rare diseases addresses critical areas where genetic testing plays a crucial role in diagnosis, treatment planning, and patient care outcomes.